- Home
- PTGX
as 07-26-2024 4:00pm EST
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 2.0B | IPO Year: | 2016 |
| Target Price: | $45.50 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.72 - $42.67 | Next Earning Date: | 08-05-2024 |
| Revenue: | $314,953,000 | Revenue Growth: | 36565.07% |
| Revenue Growth (this year): | 367.48% | Revenue Growth (next year): | -50.91% |
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Waddill William D. | PTGX | Director | Jun 7 '24 | Sell | $35.00 | 8,000 | $280,000.00 | 12,000 | SEC Form 4 |
| PATEL DINESH V PH D | PTGX | President and CEO | Jun 7 '24 | Sell | $35.19 | 35,000 | $1,231,650.00 | 515,415 | SEC Form 4 |
| Ali Asif | PTGX | Chief Financial Officer | Apr 18 '24 | Sell | $25.11 | 1,234 | $30,985.74 | 37,163 | SEC Form 4 |
| PATEL DINESH V PH D | PTGX | President and CEO | Apr 1 '24 | Sell | $28.31 | 25,000 | $707,750.00 | 549,590 | SEC Form 4 |
| PATEL DINESH V PH D | PTGX | President and CEO | Mar 1 '24 | Sell | $31.62 | 30,000 | $948,600.00 | 574,590 | SEC Form 4 |
| Waddill William D. | PTGX | Director | Mar 1 '24 | Sell | $31.34 | 12,975 | $406,636.50 | 12,000 | SEC Form 4 |
| Ali Asif | PTGX | Chief Financial Officer | Feb 29 '24 | Sell | $30.61 | 7,850 | $240,288.50 | 42,734 | SEC Form 4 |
| Ali Asif | PTGX | Chief Financial Officer | Feb 29 '24 | Sell | $31.00 | 2,089 | $64,759.00 | 40,645 | SEC Form 4 |
| Ali Asif | PTGX | Chief Financial Officer | Feb 29 '24 | Sell | $32.22 | 12,000 | $386,640.00 | 40,645 | SEC Form 4 |
| Ali Asif | PTGX | Chief Financial Officer | Feb 29 '24 | Sell | $32.33 | 2,248 | $72,677.84 | 38,397 | SEC Form 4 |
| Gupta Suneel | PTGX | Chief Development Officer | Jan 9 '24 | Sell | $25.00 | 5,000 | $125,000.00 | 187,567 | SEC Form 4 |
| PATEL DINESH V PH D | PTGX | President and CEO | Dec 13 '23 | Sell | $20.08 | 75,000 | $1,506,000.00 | 534,347 | SEC Form 4 |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Nov 15 '23 | Sell | $16.24 | 1,848 | $30,011.52 | 22,527 | SEC Form 4 |
Latest Protagonist Therapeutics Inc. News
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $48 From $39, Maintains Overweight Rating
MT Newswires
2 days ago
BTIG Raises Price Target on Protagonist Therapeutics to $51 From $41, Maintains Buy Rating
Argus Research
3 days ago
PTGX: What does Argus have to say about PTGX?
ACCESSWIRE
5 days ago
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Zacks
8 days ago
Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable
Argus Research
10 days ago
PTGX: Raising target price to $40.00
Investor's Business Daily
a month ago
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
Associated Press
a month ago
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024
Compare PTGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.